The objectives of the proposed study are to examine the effects of postnatal management approaches (non-pharmacological, including ESC versus opioid replacement pharmacotherapy) and the timing and…

Ended Definitive Contract Awarded Last action

Contract number
75F40123C00211
Awardee
Awarding agency
Obligated
$520,616

Award facts

Opportunity
Contract value 100% obligated
$520,616.02 Current and potential, with all options
Completion date 100% complete
  • Current, with exercised options
  • Potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Basic Research
Pricing
Firm Fixed Price
Place of performance
Silver Spring, MD 20993, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Close Out P00005 · The purpose of this modification is to DE-obligate funds, cancel non-funded items 3 & 4, then close out the contract. -$340,379
Other Administrative Action P00004 · EOI::columbiau/PPP::EOI $0
Terminate for Convenience P00003 · EOI:: implementing the president's department of government efficiency cost efficiency initiative :: EOI $0
Other Administrative Action P00002 $0
Exercise an Option P00001 $423,419
Original award $437,576

About this award

The Food and Drug Administration awarded a $520,616 definitive contract with firm fixed pricing to The Trustees of Columbia University in the City of New York (Health Sciences Division) on September 25, 2023, to examine the effects of postnatal management approaches for infants exposed to gestational opioids. The research will compare non-pharmacological interventions, including environmental soothing care, against opioid replacement pharmacotherapy, analyzing their impact on in-hospital outcomes relative to timing and duration of prenatal opioid exposure. The work will be performed in Silver Spring, Maryland, in support of the FDA's regulatory science initiatives. This non-set-aside contract was awarded through a Broad Agency Announcement posted in November 2021, which sought research and development proposals to develop new tools, standards, and approaches supporting safety, efficacy, and quality evaluations of FDA-regulated products.

The contract is currently undergoing modification to de-obligate funds and cancel unfunded items, with an ultimate completion date of September 29, 2025. Columbia University, a prominent academic research institution with extensive experience supporting federal agencies including the National Institutes of Health, Centers for Disease Control and Prevention, and National Heart, Lung, and Blood Institute, brings substantial biomedical research capabilities to this critical investigation of opioid-exposed infants. The research addresses an important public health concern related to neonatal opioid exposure and will contribute to evidence-based clinical management protocols for this vulnerable population.

Description

The objectives of the proposed study are to examine the effects of postnatal management approaches (non-pharmacological, including ESC versus opioid replacement pharmacotherapy) and the timing and duration of gestational opioid exposure on in-hospita

Subawards

Subcontractor Amount Awarded
Kaiser Foundation Hospitals THE OBJECTIVES OF THE PROPOSED STUDY ARE TO EXAMINE THE EFFECTS OF POSTNATAL MANAGEMENT APPROACHES (NON-PHARMACOLOGICAL, INCLUDING ESC VERSUS OPIOID REPLACEMENT… $192,826

Quick answers

Who was awarded contract 75F40123C00211?

75F40123C00211 was awarded to The Trustees Of Columbia University In The City Of New York by Food and Drug Administration (Department of Health and Human Services) on September 25, 2023.

How much is contract 75F40123C00211 worth?

The government has obligated $520,616 on 75F40123C00211.

Was contract 75F40123C00211 competed?

The extent of competition for 75F40123C00211 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award